M
Markku S. Nieminen
Researcher at University of Helsinki
Publications - 493
Citations - 73499
Markku S. Nieminen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Left ventricular hypertrophy & Heart failure. The author has an hindex of 101, co-authored 492 publications receiving 69361 citations. Previous affiliations of Markku S. Nieminen include Helsinki University Central Hospital & Oulu University Hospital.
Papers
More filters
Journal Article
Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft.
TL;DR: CMV infection is associated with intense cardiac allograft arteriosclerosis affecting the whole coronary tree soon after transplantation, indicating that the risk for graft loss and death due to chronic rejection is especially high during the first 5 post-transplant years in CMV-infected patients.
Journal ArticleDOI
Quantitative PCR analysis of salivary pathogen burden in periodontitis.
Aino Salminen,K. A. Elisa Kopra,Kati Hyvärinen,Susanna Paju,Päivi Mäntylä,Kåre Buhlin,Kåre Buhlin,Markku S. Nieminen,Juha Sinisalo,Pirkko J. Pussinen +9 more
TL;DR: Salivary diagnostics of periodontitis has potential especially in large-scale population studies and health promotion and the cumulative strategy appears to be useful in the analysis of salivary bacteria as markers ofperiodontitis.
Journal Article
Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts.
Pekka Koskinen,Leena Krogerus,Markku S. Nieminen,Severi Mattila,Pekka Häyry,Irmeli Lautenschlager +5 more
TL;DR: An inflammatory response in vessel walls with alterations of small intramyocardial arterioles leading to narrowing of the vascular lumen of the graft was associated with cytomegalovirus infection in heart transplant patients.
Journal ArticleDOI
Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study
Giovanni de Simone,Kristian Wachtell,Kristian Wachtell,Vittorio Palmieri,Vittorio Palmieri,Darcy A. Hille,Gareth Beevers,Björn Dahlöf,Ulf de Faire,F Fyhrquist,Hans Ibsen,Stevo Julius,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Richard B. Devereux +19 more
TL;DR: Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study as mentioned in this paper, which was conducted in the UK.
Journal ArticleDOI
The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study
Sverre E. Kjeldsen,Paulette A. Lyle,Jorge R. Kizer,Björn Dahlöf,Richard B. Devereux,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristianson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Steven M. Snapinn,Katherine E. Harris,Hans Wedel +18 more
TL;DR: Data suggest that losartan‐based treatment is more effective than an atenolol‐ based treatment for patients with ISH and a high risk for stroke.